NCT00244543

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of R89674 0.25% Ophthalmic Solution in Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 110 (planned)
• Sponsor: Vistakon Pharmaceuticals · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis

Conditions

• Allergic Conjunctivitis

Interventions

Type	Name	Description
DRUG	R89674 (generic name not yet established)

Timeline

• Start date: 2005-10-01
• Primary completion: 2005-11-01
• First posted: 2005-10-26
• Last updated: 2011-09-27

Locations

1 site across 1 country: United States